Biontech sales exceed two billion euros in the first quarter

The Mainz-based company Biontech generated a turnover of 2.05 billion euros in the first quarter of 2021, compared to 27.7 million euros in the same period last year.

If there is one clear winner in the coronavirus pandemic, it is the pharmaceutical industry. The Mainz-based company Biontech, which published its figures for the first quarter of 2021 on Thursday, is also feeling the effects: turnover rose from 27.7 million euros in the first quarter of 2020 to 2.05 billion euros. A quarterly loss of 58 million euros turned into a profit of 1.13 billion euros.

By May 6, Biontech and its American partner Pfizer had delivered 450 million doses of the Covid-19 vaccine worldwide. Three billion doses are to be delivered this year, and firm contracts have already been concluded for the following years to secure sales of the Covid-19 vaccine.

Biontech expects sales of 12.4 billion euros this year. The pharmaceutical company intends to invest the revenue primarily in further research into mRNA active ingredients, which are also used for Covid-19 vaccines and are to be used in cancer therapy. Biontech also intends to produce vaccines in China and has signed a letter of intent for a joint venture. The Mainz-based company's vaccine has not yet been approved there.